Abstract

Micro-nanoengineered biosensing systems have become the new promising materials in the context of allowing ultrasensitive, high-speed, and on-site sensing in point-of-care (POC) translational medicine. The platforms are based on the use of advanced micro and nanotechnology that is capable of detecting the biomarkers at high precision to allow real-time diagnostic decision-making at the bedside. The following paper discusses how such biosensing platforms should be developed and streamlined to enable them to incorporate the most recent advances in nanomaterials and microfabrication methods to increase sensitivity and specificity. The micro-nanoengineered biosensor and its fabrication, integration with detection mechanisms, and performance are elaborated. Experimental evidence demonstrates that the platform is highly sensitive and specific to detect different clinical biomarkers, being faster and more accurate compared to the conventional method. Also, the prospects of the platform being implemented in clinical setups immediately are considered, as well as the implications of making decisions on patient care more informed and prompt. The study underlines the multitude of disease types that these biosensing systems can be used to detect, as well as their ability to diagnose infectious conditions and chronic diseases, and the general revolution that they have brought to POC diagnostics. Although micro-nanoengineering biosensing systems and their scaling have proven difficult, due to scalability and lack of reproducibility, integrating micro-nanoengineered biosensing systems into the standard practice of healthcare can be used to transform how healthcare is delivered, particularly in resource-restricted environments. The results are that these platforms can help fill the gap between laboratory-based diagnostics and bedside care services, offering an important tool in personalized medicine and real-time patient monitoring.